Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

Kevin Kalinsky, Seth A. Wander, Peter A. Kaufman et al.|Journal of Clinical Oncology|2024

Cited by 75